Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

Item
http://www.wikidata.org/entity/Q35581474
The Role and Potential Therapeutic Implications of the Fibroblast Growth Factors in Energy Balance and Type 2 Diabetes.Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO miceFGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance.Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study.FGF21 Regulates Sweet and Alcohol Preference.PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates.Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.Fibroblast growth factor 21: a regulator of metabolic disease and health span.Targeting adipose tissue in the treatment of obesity-associated diabetes.Fibroblast growth factor 21 night watch: advances and uncertainties in the field.Fibroblast activation protein (FAP) as a novel metabolic target.Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing.FGF21 increases water intake, urine output and blood pressure in rats
P2860

Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

Item
http://www.wikidata.org/entity/Q35581474
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacokinetics (PK), pharmac ...... nd leptin-deficient obese mice
@ast
Pharmacokinetics (PK), pharmac ...... nd leptin-deficient obese mice
@en
type
label
Pharmacokinetics (PK), pharmac ...... nd leptin-deficient obese mice
@ast
Pharmacokinetics (PK), pharmac ...... nd leptin-deficient obese mice
@en
prefLabel
Pharmacokinetics (PK), pharmac ...... nd leptin-deficient obese mice
@ast
Pharmacokinetics (PK), pharmac ...... nd leptin-deficient obese mice
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Pharmacokinetics (PK), pharmac ...... nd leptin-deficient obese mice
@en
P2093
P2860
P304
P31
P356
10.1371/JOURNAL.PONE.0119104
P407
P433
P478
P50
P577
P5875
P698
P921
P932